2-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-isoindole-4-carboxylic acid | 902450-08-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-isoindole-4-carboxylic acid
• 英文别名: 2-(4-Methoxyphenyl)-3-oxo-1H-isoindole-4-carboxylic acid
• CAS: 902450-08-2
• 化学式: C₁₆H₁₃NO₄
• mdl: MFCD08457199
• 分子量: 283.284
• InChiKey: YQWCYYGWDGXWFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-isoindole-4-carboxylic acid 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 以76%的产率得到(2-(4-methoxyphenyl)-2,3-dihydro-1H-isoindol-4-yl)methanol
  参考文献：
  名称：

  The interaction of 4-hydroxymethyl isoindolines with dehydrobenzene. Synthesis of 3-phenylaminomethyldihydrobenzo[c]furanes

  摘要：

  2-Alkyl or 2-aryl-substituted 4-hydroxymethylisoindolines smoothly undergo intramolecular recyclization through reaction with arynes to give isobenzofurans with good yields. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2015.01.022
• 作为产物：
  描述：

  3-(4-methoxyphenyl)-4-oxo-10-oxa-3-azatricyclo[5,2,1,0(1,5)]dec-8-ene-6-carboxylic acid 在 三氟甲磺酸 、 三乙胺 作用下， 反应 0.33h， 以0.17 g的产率得到2-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-isoindole-4-carboxylic acid
  参考文献：
  名称：

  简便的质子离子液体途径 ñ取代的5-羟基-4-甲基-3-氧代异吲哚啉-1-羧酰胺和 ñ取代的3-氧代异吲哚啉-4-羧酸

  摘要：

  用质子离子液体处理高度修饰的双环[2.2.1]庚二烯， 三氟乙酸：茶 实现了定量转换为相应的 ñ-取代的5-羟基-4-甲基-3-氧代异吲哚啉-1-羧酰胺。这种方法为快速开发高度功能化的产品提供了重要的化学空间氧代异吲哚啉 并且对底物的耐受性很高。

  DOI：

  10.1039/b924835h

文献信息

• Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
  申请人：Mustelin Tomas

  公开号：US20090105240A1

  公开（公告）日：2009-04-23

  The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates to compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure also relates to methods for identifying compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome.

  本公开涉及治疗白血病、白血病前期病症、以及骨髓增生异常综合征和急性髓系白血病的方法。本公开还涉及可用于治疗白血病、白血病前期病症、以及骨髓增生异常综合征和急性髓系白血病的化合物。本公开还涉及用于识别可用于治疗白血病、白血病前期病症、以及骨髓增生异常综合征的化合物的方法。
• METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS
  申请人：Reed John C.

  公开号：US20090118135A1

  公开（公告）日：2009-05-07

  An assay for determining compounds that inhibit activity of a BCl-2 protein, or affect conversion of Bcl-2 from an antiapoptotic to a proapoptotic form are described. In addition, compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and related Bcl-2 family members are identified.
• METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME
  申请人：Mustelin Tomas

  公开号：US20120095032A1

  公开（公告）日：2012-04-19

  The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates to compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure also relates to methods for identifying compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome.